Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for Exercise Capacity in Cardiac Allograft Vasculopathy
NCT03405831Phase 4Unknown
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in cardiac allograft vasculopathy (CAV) comparing Ivabradine with Placebo (2 arms). Primary endpoint: Change in VO2max at 12 weeks. Status: unknown.
02
Drugs
ivabradine
03
Conditions
cardiac allograft vasculopathy (CAV)
Beyond the preview
Go deeper on NCT03405831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03405831.